Literature DB >> 12531932

Measuring motor complications in clinical trials for early Parkinson's disease.

C Marras, A E Lang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12531932      PMCID： PMC1738277          DOI： 10.1136/jnnp.74.2.143

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

1.  A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

Authors:  D Grosset; L Taurah; D J Burn; D MacMahon; A Forbes; K Turner; A Bowron; R Walker; L Findley; O Foster; K Patel; C Clough; B Castleton; S Smith; G Carey; T Murphy; J Hill; U Brechany; P McGee; S Reading; G Brand; L Kelly; K Breen; S Ford; M Baker; A Williams; J Hearne; N Qizilbash; K Ray Chaudhuri
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

2.  Current approaches to the treatment of Parkinson's disease.

Authors:  Joseph Jankovic; L Giselle Aguilar
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

3.  Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.

Authors:  Gyan Modi; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  J Med Chem       Date:  2014-02-12       Impact factor: 7.446
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.